Fine epitope specificity of antibodies against interleukin-2 explains their paradoxical immunomodulatory effects

References

• Malek TR, Bayer AL. Tolerance, not immunity, crucially depends on IL-2. Nat Rev Immunol 2004; 4:665 - 74; http://dx.doi.org/10.1038/nri1435; PMID: 15343366
   PubMed Web of Science ®Google Scholar
• Hoyer KK, Dooms H, Barron L, Abbas AK. Interleukin-2 in the development and control of inflammatory disease. Immunol Rev 2008; 226:19 - 28; http://dx.doi.org/10.1111/j.1600-065X.2008.00697.x; PMID: 19161413
   PubMed Web of Science ®Google Scholar
• Liao W, Lin J-X, Leonard WJ. Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy. Immunity 2013; 38:13 - 25; http://dx.doi.org/10.1016/j.immuni.2013.01.004; PMID: 23352221
   PubMed Web of Science ®Google Scholar
• Cesana GC, DeRaffele G, Cohen S, Moroziewicz D, Mitcham J, Stoutenburg J, Cheung K, Hesdorffer C, Kim-Schulze S, Kaufman HL. Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma. J Clin Oncol 2006; 24:1169 - 77; http://dx.doi.org/10.1200/JCO.2005.03.6830; PMID: 16505437
   PubMed Web of Science ®Google Scholar
• Boyman O, Kovar M, Rubinstein MP, Surh CD, Sprent J. Selective stimulation of T cell subsets with antibody-cytokine immune complexes. Science 2006; 311:1924 - 7; http://dx.doi.org/10.1126/science.1122927; PMID: 16484453
   PubMed Web of Science ®Google Scholar
• Kamimura D, Sawa Y, Sato M, Agung E, Hirano T, Murakami M. IL-2 in vivo activities and antitumor efficacy enhanced by an anti-IL-2 mAb. J Immunol 2006; 177:306 - 14; PMID: 16785526
   PubMed Web of Science ®Google Scholar
• Mostböck S, Lutsiak ME, Milenic DE, Baidoo K, Schlom J, Sabzevari H. IL-2/anti-IL-2 antibody complex enhances vaccine-mediated antigen-specific CD8+ T cell responses and increases the ratio of effector/memory CD8+ T cells to regulatory T cells. J Immunol 2008; 180:5118 - 29; PMID: 18354238
   PubMed Web of Science ®Google Scholar
• Tomala J, Chmelova H, Mrkvan T, Rihova B, Kovar M. In vivo expansion of activated naive CD8+ T cells and NK cells driven by complexes of IL-2 and anti-IL-2 monoclonal antibody as novel approach of cancer immunotherapy. J Immunol 2009; 183:4904 - 12; http://dx.doi.org/10.4049/jimmunol.0900284; PMID: 19801515
   PubMed Web of Science ®Google Scholar
• Kohyama K, Sugiura H, Kozawa E, Wasa J, Yamada K, Nishioka A, Kamei Y, Taguchi O. Antitumor activity of an interleukin-2 monoclonal antibody in a murine osteosarcoma transplantation model. Anticancer Res 2012; 32:779 - 82; PMID: 22399592
   PubMed Web of Science ®Google Scholar
• Webster KE, Walters S, Kohler RE, Mrkvan T, Boyman O, Surh CD, Grey ST, Sprent J. In vivo expansion of T reg cells with IL-2-mAb complexes: induction of resistance to EAE and long-term acceptance of islet allografts without immunosuppression. J Exp Med 2009; 206:751 - 60; http://dx.doi.org/10.1084/jem.20082824; PMID: 19332874
   PubMed Web of Science ®Google Scholar
• Liu R, Zhou Q, La Cava A, Campagnolo DI, Van Kaer L, Shi F-D. Expansion of regulatory T cells via IL-2/anti-IL-2 mAb complexes suppresses experimental myasthenia. Eur J Immunol 2010; 40:1577 - 89; http://dx.doi.org/10.1002/eji.200939792; PMID: 20352624
   PubMed Web of Science ®Google Scholar
• Liu C-L, Ye P, Yen BC, Miao CH. In vivo expansion of regulatory T cells with IL-2/IL-2 mAb complexes prevents anti-factor VIII immune responses in hemophilia A mice treated with factor VIII plasmid-mediated gene therapy. Mol Ther 2011; 19:1511 - 20; http://dx.doi.org/10.1038/mt.2011.61; PMID: 21468007
   PubMed Web of Science ®Google Scholar
• Lee S-Y, Cho M-L, Oh H-J, Ryu J-G, Park M-J, Jhun J-Y, Park M-K, Stone JC, Ju J-H, Hwang S-Y, et al. Interleukin-2/anti-interleukin-2 monoclonal antibody immune complex suppresses collagen-induced arthritis in mice by fortifying interleukin-2/STAT5 signalling pathways. Immunology 2012; 137:305 - 16; http://dx.doi.org/10.1111/imm.12008; PMID: 23167249
   PubMed Web of Science ®Google Scholar
• Boyman O, Surh CD, Sprent J. Potential use of IL-2/anti-IL-2 antibody immune complexes for the treatment of cancer and autoimmune disease. Expert Opin Biol Ther 2006; 6:1323 - 31; http://dx.doi.org/10.1517/14712598.6.12.1323; PMID: 17223740
   PubMed Web of Science ®Google Scholar
• Rojas G, Pupo A, Leon K, Avellanet J, Carmenate T, Sidhu S. Deciphering the molecular bases of the biological effects of antibodies against Interleukin-2: a versatile platform for fine epitope mapping. Immunobiology 2013; 218:105 - 13; http://dx.doi.org/10.1016/j.imbio.2012.02.009; PMID: 22459271
   PubMed Web of Science ®Google Scholar
• Chasteen L, Ayriss J, Pavlik P, Bradbury AR. Eliminating helper phage from phage display. Nucleic Acids Res 2006; 34:e145; http://dx.doi.org/10.1093/nar/gkl772; PMID: 17088290
   PubMed Web of Science ®Google Scholar
• Buchli PJ, Wu Z, Ciardelli TL. The functional display of interleukin-2 on filamentous phage. Arch Biochem Biophys 1997; 339:79 - 84; http://dx.doi.org/10.1006/abbi.1996.9853; PMID: 9056236
   PubMed Web of Science ®Google Scholar
• Vispo NS, Callejo M, Ojalvo AG, Santos A, Chinea G, Gavilondo JV, Araña MJ. Displaying human interleukin-2 on the surface of bacteriophage. Immunotechnology 1997; 3:185 - 93; http://dx.doi.org/10.1016/S1380-2933(97)00012-2; PMID: 9358271
   PubMedGoogle Scholar
• Felici F, Castagnoli L, Musacchio A, Jappelli R, Cesareni G. Selection of antibody ligands from a large library of oligopeptides expressed on a multivalent exposition vector. J Mol Biol 1991; 222:301 - 10; http://dx.doi.org/10.1016/0022-2836(91)90213-P; PMID: 1720463
   PubMed Web of Science ®Google Scholar
• Deroo S, Muller CP. Antigenic and immunogenic phage displayed mimotopes as substitute antigens: applications and limitations. Comb Chem High Throughput Screen 2001; 4:75 - 110; http://dx.doi.org/10.2174/1386207013331309; PMID: 11281827
   PubMed Web of Science ®Google Scholar
• Menendez A, Scott JK. The nature of target-unrelated peptides recovered in the screening of phage-displayed random peptide libraries with antibodies. Anal Biochem 2005; 336:145 - 57; http://dx.doi.org/10.1016/j.ab.2004.09.048; PMID: 15620878
   PubMed Web of Science ®Google Scholar
• Saphire EO, Montero M, Menendez A, van Houten NE, Irving MB, Pantophlet R, Zwick MB, Parren PWHI, Burton DR, Scott JK, et al. Structure of a high-affinity “mimotope” peptide bound to HIV-1-neutralizing antibody b12 explains its inability to elicit gp120 cross-reactive antibodies. J Mol Biol 2007; 369:696 - 709; http://dx.doi.org/10.1016/j.jmb.2007.01.060; PMID: 17445828
   PubMed Web of Science ®Google Scholar
• Vispo NS, Araña MJ, Chinea G, Ojalvo AG, Cesareni G. Characterization of epitopes on human interleukin-2 using phage displayed-peptide libraries: insights into antibody-peptide interactions. Hybridoma 1999; 18:251 - 5; http://dx.doi.org/10.1089/027245799315907; PMID: 10475239
   PubMed Web of Science ®Google Scholar
• Davies DR, Padlan EA, Sheriff S. Antibody-antigen complexes. Annu Rev Biochem 1990; 59:439 - 73; http://dx.doi.org/10.1146/annurev.bi.59.070190.002255; PMID: 2197980
   PubMed Web of Science ®Google Scholar
• Braden BC, Poljak RJ. Structural features of the reactions between antibodies and protein antigens. FASEB J 1995; 9:9 - 16; PMID: 7821765
   PubMed Web of Science ®Google Scholar
• Davies DR, Cohen GH. Interactions of protein antigens with antibodies. Proc Natl Acad Sci U S A 1996; 93:7 - 12; http://dx.doi.org/10.1073/pnas.93.1.7; PMID: 8552677
   PubMed Web of Science ®Google Scholar
• Wang X, Rickert M, Garcia KC. Structure of the quaternary complex of interleukin-2 with its α, β, and gammac receptors. Science 2005; 310:1159 - 63; http://dx.doi.org/10.1126/science.1117893; PMID: 16293754
   PubMed Web of Science ®Google Scholar
• Stauber DJ, Debler EW, Horton PA, Smith KA, Wilson IA. Crystal structure of the IL-2 signaling complex: paradigm for a heterotrimeric cytokine receptor. Proc Natl Acad Sci U S A 2006; 103:2788 - 93; http://dx.doi.org/10.1073/pnas.0511161103; PMID: 16477002
   PubMed Web of Science ®Google Scholar
• Phelan JD, Orekov T, Finkelman FD. Cutting edge: mechanism of enhancement of in vivo cytokine effects by anti-cytokine monoclonal antibodies. J Immunol 2008; 180:44 - 8; PMID: 18097002
   PubMed Web of Science ®Google Scholar
• Tomala J, Kovarova J, Kabesova M, Votavova P, Chmelova H, Dvorakova B, Rihova B, Kovar M. Chimera of IL-2 linked to light chain of anti-IL-2 mAb mimics IL-2/anti-IL-2 mAb complexes both structurally and functionally. ACS Chem Biol 2013; 8:871 - 6; http://dx.doi.org/10.1021/cb3007242; PMID: 23419043
   PubMed Web of Science ®Google Scholar
• Carmenate T, Pacios A, Enamorado M, Moreno E, Garcia-Martínez K, Fuente D, León K. Human IL-2 mutein with higher antitumor efficacy than wild type IL-2. J Immunol 2013; 190:6230 - 8; http://dx.doi.org/10.4049/jimmunol.1201895; PMID: 23677467
   PubMed Web of Science ®Google Scholar
• García-Martínez K, León K. Modeling the role of IL2 in the interplay between CD4+ helper and regulatory T cells: studying the impact of IL2 modulation therapies. Int Immunol 2012; 24:427 - 46; http://dx.doi.org/10.1093/intimm/dxr120; PMID: 22371423
   PubMed Web of Science ®Google Scholar
• Malek TR, Castro I. Interleukin-2 receptor signaling: at the interface between tolerance and immunity. Immunity 2010; 33:153 - 65; http://dx.doi.org/10.1016/j.immuni.2010.08.004; PMID: 20732639
   PubMed Web of Science ®Google Scholar
• Nakamura M, Asao H, Takeshita T, Sugamura K. Interleukin-2 receptor heterotrimer complex and intracellular signaling. Semin Immunol 1993; 5:309 - 17; http://dx.doi.org/10.1006/smim.1993.1037; PMID: 8260647
   PubMedGoogle Scholar
• Zurawski SM, Mosmann TR, Benedik M, Zurawski G. Alterations in the amino-terminal third of mouse interleukin 2: effects on biological activity and immunoreactivity. J Immunol 1986; 137:3354 - 60; PMID: 2430019
   PubMed Web of Science ®Google Scholar
• Marks JD, Hoogenboom HR, Bonnert TP, McCafferty J, Griffiths AD, Winter G. By-passing immunization. Human antibodies from V-gene libraries displayed on phage. J Mol Biol 1991; 222:581 - 97; http://dx.doi.org/10.1016/0022-2836(91)90498-U; PMID: 1748994
   PubMed Web of Science ®Google Scholar
• Kunkel TA. Rapid and efficient site-specific mutagenesis without phenotypic selection. Proc Natl Acad Sci U S A 1985; 82:488 - 92; http://dx.doi.org/10.1073/pnas.82.2.488; PMID: 3881765
   PubMed Web of Science ®Google Scholar
• Fellouse FA, Sidhu SS. Making antibodies in bacteria. In Making and using antibodies. A practical handbook. G.C. Howard, and M.R.Kaser, CRC Press, Boca Raton, Florida, 2007, pp 157-177.
   Google Scholar